180 related articles for article (PubMed ID: 2144705)
21. Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris.
Hiasa Y; Hamai K; Wada T; Aihara T; Bando M; Nakai Y; Kataoka Y
Tokushima J Exp Med; 1989 Dec; 36(3-4):65-70. PubMed ID: 2534651
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris.
Kinoshita M; Nishikawa S; Sawamura M; Yamaguchi S; Mitsunami K; Itoh M; Motomura M; Bito K; Mashiro I; Kawakita S
Am J Cardiol; 1986 Oct; 58(9):733-8. PubMed ID: 2945420
[TBL] [Abstract][Full Text] [Related]
23. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.
Markham A; Plosker GL; Goa KL
Drugs; 2000 Oct; 60(4):955-74. PubMed ID: 11085202
[TBL] [Abstract][Full Text] [Related]
24. A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris.
Maltz MB; Dymond DS; Nathan AW; Camm AJ
Eur Heart J; 1987 Dec; 8 Suppl M():37-42. PubMed ID: 2967184
[TBL] [Abstract][Full Text] [Related]
25. Duration of effects of isradipine during twice daily therapy in angina pectoris.
Thadani U; Chrysant S; Gorwit J; Giles T; Archer S; Iteld B; Singh S; Copen D; Wakeford C; Hobbs S
Cardiovasc Drugs Ther; 1994 Apr; 8(2):199-210. PubMed ID: 7918132
[TBL] [Abstract][Full Text] [Related]
26. Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris.
Salonen JT; Taskinen E; Salonen R; Seppänen K; Venäläinen J; Rauramaa R
Am J Cardiol; 1986 Nov; 58(12):35E-40E. PubMed ID: 2878600
[TBL] [Abstract][Full Text] [Related]
27. Management of chronic stable angina with once-daily bisoprolol or atenolol and long-term efficacy of bisoprolol.
Kohli RS; Lahiri A; Raftery EB
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S148-53. PubMed ID: 2439787
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
De Backer GG; Derese A
Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA).
de Muinck ED; Buchner-Moell D; van de Ven LL; Lie KI
J Cardiovasc Pharmacol; 1992 Jun; 19(6):870-5. PubMed ID: 1376806
[TBL] [Abstract][Full Text] [Related]
30. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.
Silke B; Verma SP; Ali MS; Goldhammer E; Taylor SH
Am J Cardiol; 1989 Jun; 63(21):49J-55J. PubMed ID: 2525326
[TBL] [Abstract][Full Text] [Related]
31. Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.
Pedersen TR; Kantor M
Cardiovasc Drugs Ther; 1990 Apr; 4(2):451-6. PubMed ID: 2285629
[TBL] [Abstract][Full Text] [Related]
32. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Roland E
Eur Heart J; 1993 Jul; 14 Suppl B():48-52. PubMed ID: 8370373
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of nicorandil in congestive heart failure.
Galié N; Varani E; Maiello L; Boriani G; Boschi S; Binetti G; Magnani B
Am J Cardiol; 1990 Feb; 65(5):343-8. PubMed ID: 2137279
[TBL] [Abstract][Full Text] [Related]
34. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test.
Kato K; Asanoi H; Wakabayashi C; Hosoda S; Shiina A; Hosono K; Kurita A; Seki K; Ishida K; Kuroiwa A
J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S98-103. PubMed ID: 2447432
[TBL] [Abstract][Full Text] [Related]
35. Comparison of atenolol and nifedipine in chronic stable angina pectoris.
Shapiro W; Narahara KA; Kostis JB; Thandroyen F; Zohman LR
Am J Cardiol; 1989 Jul; 64(3):186-90. PubMed ID: 2662743
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the duration of action of atenolol and nadolol for treatment of angina pectoris.
Kostis JB
Am J Cardiol; 1988 Dec; 62(17):1171-5. PubMed ID: 3057850
[TBL] [Abstract][Full Text] [Related]
37. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
Döring G
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S74-81. PubMed ID: 1282180
[TBL] [Abstract][Full Text] [Related]
38. [A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate].
Lai C; Onnis E; Solinas R; Orani E; Lai G; Cadeddu M; Cherchi A
Cardiologia; 1991 Sep; 36(9):703-11. PubMed ID: 1839369
[TBL] [Abstract][Full Text] [Related]
39. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate.
Thadani U; Maranda CR; Amsterdam E; Spaccavento L; Friedman RG; Chernoff R; Zellner S; Gorwit J; Hinderaker PH
Ann Intern Med; 1994 Mar; 120(5):353-9. PubMed ID: 8093132
[TBL] [Abstract][Full Text] [Related]
40. Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris.
Schwartz JB; Jackson G; Kates RE; Harrison DC
Am Heart J; 1981 Apr; 101(4):380-5. PubMed ID: 6111212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
